Metropolis Healthcare’s board approved a 3:1 bonus share issue and reviewed the unaudited financial results for Q3 2026. The company also approved the sale of its External Quality Assessment Services (EQAS) division to Metropolis Quality Solutions Private Limited for up to INR 1.25 crore. Financial performance details are outlined below, showcasing the company’s continued growth and strategic business decisions.
Financial Performance: Q3 2026
Metropolis Healthcare announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Key highlights include:
Key Financial Figures (Standalone)
- Total Income: INR 336.99 million
- Profit Before Tax: INR 423.20 million
- Profit After Tax: INR 320.32 million
Key Financial Figures (Consolidated)
- Total Income: INR 414.92 million
- Profit Before Tax: INR 571.56 million
- Profit After Tax: INR 420.87 million
Bonus Issue Approval
The Board approved a bonus issue of equity shares in the ratio of 3:1, meaning three bonus equity shares for every one existing share. This is subject to shareholder and regulatory approvals. The record date for determining shareholder eligibility for the bonus issue will be announced separately.
Divestiture of EQAS Division
The Board approved the sale and transfer of its External Quality Assessment Services (EQAS) business to Metropolis Quality Solutions Private Limited (MQSPL), a wholly-owned subsidiary, for a consideration of up to INR 1.25 crore. The consideration will be discharged by MQSPL either in cash, through the issuance of its equity shares, or a combination of both. Completion of the transfer is subject to fulfilling conditions precedent.
Other Key Updates
- The Board also approved grants of Restricted Stock Units (RSU) and Employee Stock Options to eligible employees under the company’s existing plans.
Source: BSE
